{"id":"NCT02973503","sponsor":"University Hospital, Clermont-Ferrand","briefTitle":"Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis","officialTitle":"A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-11","primaryCompletion":"2018-11-10","completion":"2019-04","firstPosted":"2016-11-25","resultsPosted":"2020-09-07","lastUpdate":"2020-10-01"},"enrollment":117,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic HCV Infection"],"interventions":[{"type":"DRUG","name":"Elbasvir/Grazoprevir Fixed Dose Combination","otherNames":[]}],"arms":[{"label":"Elbasvir/Grazoprevir","type":"EXPERIMENTAL"}],"summary":"A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non-severe fibrosis\n\nThe primary objectives of this study are as follows:\n\n* To evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).\n* To evaluate the safety and tolerability of EBV/GZR treatment\n\nThe secondary objectives of this study are as follows:\n\n* To determine the proportion of subjects who attain SVR at 4 and 24 weeks after cessation of treatment (SVR4 and SVR24)\n* To evaluate the proportion of subjects with virologic failure\n* To evaluate the kinetics of circulating HCV RNA during treatment and after cessation of treatment.\n* To evaluate the emergence of viral resistance to EBV/GZR during treatment and after cessation of treatment","primaryOutcome":{"measure":"Evaluation of the Efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve as Measured by the Proportion of Subjects With Sustained Viral Response 12 Weeks After Cessation of Treatment (SVR 12).","timeFrame":"at 12 weeks post-treatment","effectByArm":[{"arm":"Elbasvir/Grazoprevir","deltaMin":109,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":15},"locations":{"siteCount":1,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":117},"commonTop":["ASTHENIA","HEADACHE","DIGESTIVE DISORDERS"]}}